Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Tegaserod + omeprazole** is an unbranded, non-standard combination therapy composed of two well-characterized drugs: **tegaserod**, a selective serotonin type-4 (5-HT4) receptor agonist used to stimulate gastrointestinal motility, and **omeprazole**, a proton pump inhibitor (PPI) that suppresses gastric acid secretion. Tegaserod mainly acts by activating 5-HT4 receptors to increase peristalsis and reduce visceral sensitivity, beneficial for conditions with impaired gut motility. Omeprazole irreversibly inhibits the H+/K+ ATPase in gastric parietal cells, reducing acid secretion and alleviating symptoms of acid reflux and dyspepsia. The combination has been trialed for functional dyspepsia and gastroesophageal reflux disease (GERD) in patients with chronic constipation, where it demonstrated efficacy and safety, with superior symptom relief compared to esomeprazole alone or either drug alone. There is no commercial product with this exact composition; use in studies is investigational[3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tegaserod + omeprazole.